In the Journals

OCT provides prognostic data in patients with CRVO

Optical coherence tomography may provide predictive information after 3 months of treatment with ranibizumab in patients with central retinal vein occlusion, according to a study.

Investigators evaluated time-domain OCT findings for 397 branch retinal vein occlusion patients from the BRAVO study and 392 central retinal vein occlusion patients from the CRUISE study. Patients received 0.3-mg or 0.5-mg injections of Lucentis (ranibizumab, Genentech) or placebo.

In the CRUISE study, 71.2% of patients in the 0.3-mg group and 78.5% of patients in the 0.5-mg group had central foveal thickness of 250 µm or less at 3 months. In the BRAVO study, 79.1% of patients in the 0.3-mg group and 84.7% of patients in the 0.5-mg group had central foveal thickness of 250 µm or less. These patients were classified as early responders to ranibizumab.

Visual outcomes were good in early responders regardless of dose.

Late or incomplete responders with CRVO and central foveal thickness greater than 250 µm treated with 0.3-mg injections had significantly poorer visual outcomes at 3 months (P = .012) and 12 months (P = .0084).

The differential benefit between early responders and late or incomplete responders in the BRVO group was less pronounced.

Optical coherence tomography may provide predictive information after 3 months of treatment with ranibizumab in patients with central retinal vein occlusion, according to a study.

Investigators evaluated time-domain OCT findings for 397 branch retinal vein occlusion patients from the BRAVO study and 392 central retinal vein occlusion patients from the CRUISE study. Patients received 0.3-mg or 0.5-mg injections of Lucentis (ranibizumab, Genentech) or placebo.

In the CRUISE study, 71.2% of patients in the 0.3-mg group and 78.5% of patients in the 0.5-mg group had central foveal thickness of 250 µm or less at 3 months. In the BRAVO study, 79.1% of patients in the 0.3-mg group and 84.7% of patients in the 0.5-mg group had central foveal thickness of 250 µm or less. These patients were classified as early responders to ranibizumab.

Visual outcomes were good in early responders regardless of dose.

Late or incomplete responders with CRVO and central foveal thickness greater than 250 µm treated with 0.3-mg injections had significantly poorer visual outcomes at 3 months (P = .012) and 12 months (P = .0084).

The differential benefit between early responders and late or incomplete responders in the BRVO group was less pronounced.